Back to search
Triple-Negative Breast Cancer (TNBC)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Triple-Negative Breast Cancer (TNBC) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Triple-Negative Breast Cancer (TNBC) trials you may qualify forThis study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmaco…
This phase IIa trial studies how well dendritic cell vaccines against Her2/Her3 and pembrolizumab work for the treatment of triple negative breast cancer or HER…
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieve…
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with a…
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which ty…
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and work by blocking protein interactions that normally prevent the immune system from…
The purpose of this study is to learn about the effects of the study treatment, Dendritic Cell Vaccine (DCV), to find the highest dose of the study treatment th…
The purpose of this study was to determine whether treatment with alpelisib in combination with nab-paclitaxel is safe and effective in subjects with advanced t…
International, randomised, open label, neo-adjuvant phase II trial in women with newly diagnosed, non-metastatic, high-risk (node positive and/or tumour size ≥…